Low rates of invasive fungal disease in patients with multiple myeloma managed with new generation therapies: Results from a multi‐centre cohort study

A multi‐centre study to determine the outcomes and risks for invasive fungal disease (IFD) in myeloma (MM) patients treated with second‐generation immunomodulatory drugs, proteasome inhibitors and monoclonal antibodies was conducted.

[1]  W. Jędrzejczak,et al.  Infectious Complications in Patients With Multiple Myeloma After High-Dose Chemotherapy Followed by Autologous Stem Cell Transplant: Nationwide Study of the Infectious Complications Study Group of the Polish Adult Leukemia Group. , 2020, Transplantation proceedings.

[2]  J. Perfect,et al.  Revision and Update of the Consensus Definitions of Invasive Fungal Disease From the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium , 2019, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[3]  J. Trubiano,et al.  Cryptococcal infection in patients with haematological and solid organ malignancy in the era of targeted and immune-based therapies. , 2019, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[4]  L. Rybicki,et al.  Early infectious complications after autologous hematopoietic cell transplantation for multiple myeloma , 2019, Transplant infectious disease : an official journal of the Transplantation Society.

[5]  Shuku Sato,et al.  Disseminated Cryptococcosis in a Patient with Multiple Myeloma Treated with Daratumumab, Lenalidomide, and Dexamethasone , 2018, Internal medicine.

[6]  G. Ippolito,et al.  ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Agents targeting lymphoid or myeloid cells surface antigens [II]: CD22, CD30, CD33, CD38, CD40, SLAMF-7 and CCR4). , 2018, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[7]  P. Richardson,et al.  Current use of monoclonal antibodies in the treatment of multiple myeloma , 2018, British journal of haematology.

[8]  M. Dimopoulos,et al.  A predictive model for risk of early grade ≥ 3 infection in patients with multiple myeloma not eligible for transplant: analysis of the FIRST trial , 2018, Leukemia.

[9]  F. D'Alo',et al.  Invasive fungal infections in chronic lymphoproliferative disorders: a monocentric retrospective study , 2017, Haematologica.

[10]  H. Goldschmidt,et al.  Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma. , 2016, The New England journal of medicine.

[11]  H. Goldschmidt,et al.  International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. , 2016, The Lancet. Oncology.

[12]  A. Palumbo,et al.  Clinical efficacy and management of monoclonal antibodies targeting CD38 and SLAMF7 in multiple myeloma. , 2016, Blood.

[13]  He Huang,et al.  Epidemiology and treatment of invasive fungal diseases in patients with multiple myeloma: findings from a multicenter prospective study from China , 2016, Tumor Biology.

[14]  S. Harrison,et al.  Invasive fungal infections in patients with multiple myeloma: a multi-center study in the era of novel myeloma therapies , 2015, Haematologica.

[15]  M. Pellegrini,et al.  Changing treatment paradigms for patients with plasma cell myeloma: impact upon immune determinants of infection. , 2014, Blood reviews.

[16]  M. Naunton.  Lenalidomide and dexamethasone for multiple myeloma , 2013 .

[17]  R. Takimoto,et al.  Epidemiology and treatment outcome of invasive fungal infections in patients with hematological malignancies , 2012, International Journal of Hematology.

[18]  S. Seeber,et al.  Immune parameters in multiple myeloma patients: influence of treatment and correlation with opportunistic infections , 2006, Leukemia & lymphoma.